Our workflow has been shown to be useful in determining the somatic, tumor-specific nature of driver TP53 mutations; by providing cancer-enriched samples, downstream and more complex genetic analyses such as for instance BRCA mutation screening may be facilitated and more cost-effective, as coverage may be lowered as a consequence of an increased abundance of starting tumor-derived DNA. Here, TP53 is linked to neoplasm.